SCHEMBL16884474

SCHEMBL16884474

CC(C)Oc1cc(O)cc2c1C(=O)C(O)C(c1ccc(O)c(O)c1)O2

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 4/20 0.69
▸ ALOX15 P16050 4/20 0.69
▸ MAPT P10636 3/20 0.69
▸ HSD17B10 Q99714 3/20 0.69
▸ RECQL P46063 2/20 0.69
▸ SOST Q9BQB4 2/20 0.69
▸ MEN1 O00255 2/20 0.69
▸ KMT2A Q03164 2/20 0.69
▸ KDM4E B2RXH2 2/20 0.69
▸ GAA P10253 2/20 0.69
▸ ALOX12 P18054 2/20 0.69
▸ HIF1A Q16665 2/20 0.69
▸ POLB P06746 1/20 0.69
▸ CYP1A2 P05177 1/20 0.69
▸ NFKB1 P19838 1/20 0.69
▸ MAPK1 P28482 1/20 0.69
▸ XDH P47989 2/20 0.60
▸ SYNJ2 O15056 3/20 0.58
▸ IDO1 P14902 1/20 0.53
▸ NSD2 O96028 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23353527 1.00 CYP3A4 (0.69) CYP3A4ALOX15MAPTHSD17B10RECQL
SCHEMBL16887994 0.87 XDH (0.73) CYP3A4ALOX15MAPTHSD17B10RECQL
SCHEMBL16884531 0.87 CYP3A4 (0.69) CYP3A4ALOX15MAPTHSD17B10RECQL
SCHEMBL16884496 0.87 CYP3A4 (0.69) CYP3A4ALOX15MAPTHSD17B10RECQL
SCHEMBL16884478 0.85 CYP3A4 (0.70) CYP3A4ALOX15MAPTHSD17B10RECQL
SCHEMBL23353528 0.85 CYP3A4 (0.70) CYP3A4ALOX15MAPTHSD17B10RECQL
(+)-Taxifolin SCHEMBL18131936 0.82 CYP3A4 (0.90) CYP3A4ALOX15MAPTHSD17B10RECQL
(+)-Taxifolin SCHEMBL7628142 0.82 CYP3A4 (1.00) CYP3A4ALOX15MAPTHSD17B10RECQL
(+)-Taxifolin SCHEMBL296323 0.82 CYP3A4 (1.00) CYP3A4ALOX15MAPTHSD17B10RECQL
(+)-Taxifolin SCHEMBL1707803 0.82 CYP3A4 (1.00) CYP3A4ALOX15MAPTHSD17B10RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150191430-A1 CONJUGATES OF HUPERZINE AND ANALOGS THEREOF BISCAYNE NEUROTHERAPEUTICS, INC. 2015-07-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191430-A1 CONJUGATES OF HUPERZINE AND ANALOGS THEREOF HTT, HNMT, GAP43 CYP3A4 2126/4885ALOX15 686/4885MAPT 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback